The Experts below are selected from a list of 30048 Experts worldwide ranked by ideXlab platform

Ik-kyung Jang - One of the best experts on this subject based on the ideXlab platform.

  • causes assessment and treatment of Stent Thrombosis intravascular imaging insights
    Nature Reviews Cardiology, 2015
    Co-Authors: Daniel S. Ong, Ik-kyung Jang
    Abstract:

    Stent Thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In addition to clinical and pathological studies, intravascular imaging has advanced our understanding of the mechanisms underlying Stent Thrombosis. In particular, intravascular imaging has been used to study Stent underexpansion, malapposition, uncovered struts, and neoatherosclerosis as risk factors for Stent Thrombosis. Intravascular ultrasonography and optical coherence tomography can be used to guide Stent implantation and minimize the risk of Stent Thrombosis. Additionally, optical coherence tomography offers the unique potential to tailor treatment of Stent Thrombosis to address the specific mechanism underlying the thrombotic event. Bioresorbable Stent technologies have been introduced with the goal of further reducing the incidence of Stent Thrombosis, and intravascular imaging has had an integral role in the development and assessment of these new devices. In this Review, we present insights gained through intravascular imaging into the causes of Stent Thrombosis, and the potential utility of intravascular imaging in the optimization of Stent deployment and treatment of Stent Thrombosis events.

  • Causes, assessment, and treatment of Stent Thrombosis—intravascular imaging insights
    Nature reviews. Cardiology, 2015
    Co-Authors: Daniel S. Ong, Ik-kyung Jang
    Abstract:

    Stent Thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In addition to clinical and pathological studies, intravascular imaging has advanced our understanding of the mechanisms underlying Stent Thrombosis. In particular, intravascular imaging has been used to study Stent underexpansion, malapposition, uncovered struts, and neoatherosclerosis as risk factors for Stent Thrombosis. Intravascular ultrasonography and optical coherence tomography can be used to guide Stent implantation and minimize the risk of Stent Thrombosis. Additionally, optical coherence tomography offers the unique potential to tailor treatment of Stent Thrombosis to address the specific mechanism underlying the thrombotic event. Bioresorbable Stent technologies have been introduced with the goal of further reducing the incidence of Stent Thrombosis, and intravascular imaging has had an integral role in the development and assessment of these new devices. In this Review, we present insights gained through intravascular imaging into the causes of Stent Thrombosis, and the potential utility of intravascular imaging in the optimization of Stent deployment and treatment of Stent Thrombosis events.

Peter B Berger - One of the best experts on this subject based on the ideXlab platform.

  • timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin
    American Journal of Cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary Stents treated with aspirin and coumadin, the peak incidence of Stent Thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of Stent Thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced Stent Thrombosis after successful coronary Stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from Stent implantation to Stent Thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p <0.0001). There was no significant difference between the timing of Stent Thrombosis in patients treated with abciximab in addition to ticlopidine and aspirin (median 17 hours, interquartile range 6 to 29) versus ticlopidine and aspirin patients who did not receive abciximab (median 11 hours, interquartile range 9 to 12, p = 0.57). Thus, in patients who receive coronary Stents, Stent Thrombosis occurs much earlier after the procedure in patients treated with ticlopidine and aspirin than in patients treated with anticoagulation therapy.

  • Timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin.
    The American journal of cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary Stents treated with aspirin and coumadin, the peak incidence of Stent Thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of Stent Thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced Stent Thrombosis after successful coronary Stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from Stent implantation to Stent Thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p

Daniel S. Ong - One of the best experts on this subject based on the ideXlab platform.

  • causes assessment and treatment of Stent Thrombosis intravascular imaging insights
    Nature Reviews Cardiology, 2015
    Co-Authors: Daniel S. Ong, Ik-kyung Jang
    Abstract:

    Stent Thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In addition to clinical and pathological studies, intravascular imaging has advanced our understanding of the mechanisms underlying Stent Thrombosis. In particular, intravascular imaging has been used to study Stent underexpansion, malapposition, uncovered struts, and neoatherosclerosis as risk factors for Stent Thrombosis. Intravascular ultrasonography and optical coherence tomography can be used to guide Stent implantation and minimize the risk of Stent Thrombosis. Additionally, optical coherence tomography offers the unique potential to tailor treatment of Stent Thrombosis to address the specific mechanism underlying the thrombotic event. Bioresorbable Stent technologies have been introduced with the goal of further reducing the incidence of Stent Thrombosis, and intravascular imaging has had an integral role in the development and assessment of these new devices. In this Review, we present insights gained through intravascular imaging into the causes of Stent Thrombosis, and the potential utility of intravascular imaging in the optimization of Stent deployment and treatment of Stent Thrombosis events.

  • Causes, assessment, and treatment of Stent Thrombosis—intravascular imaging insights
    Nature reviews. Cardiology, 2015
    Co-Authors: Daniel S. Ong, Ik-kyung Jang
    Abstract:

    Stent Thrombosis is a rare, but serious, complication of percutaneous coronary intervention and is associated with severe morbidity and mortality. In addition to clinical and pathological studies, intravascular imaging has advanced our understanding of the mechanisms underlying Stent Thrombosis. In particular, intravascular imaging has been used to study Stent underexpansion, malapposition, uncovered struts, and neoatherosclerosis as risk factors for Stent Thrombosis. Intravascular ultrasonography and optical coherence tomography can be used to guide Stent implantation and minimize the risk of Stent Thrombosis. Additionally, optical coherence tomography offers the unique potential to tailor treatment of Stent Thrombosis to address the specific mechanism underlying the thrombotic event. Bioresorbable Stent technologies have been introduced with the goal of further reducing the incidence of Stent Thrombosis, and intravascular imaging has had an integral role in the development and assessment of these new devices. In this Review, we present insights gained through intravascular imaging into the causes of Stent Thrombosis, and the potential utility of intravascular imaging in the optimization of Stent deployment and treatment of Stent Thrombosis events.

David R Holmes - One of the best experts on this subject based on the ideXlab platform.

  • Circadian Variation in Coronary Stent Thrombosis
    JACC. Cardiovascular interventions, 2011
    Co-Authors: Karim D. Mahmoud, Charanjit S Rihal, Ryan J. Lennon, Henry H. Ting, David R Holmes
    Abstract:

    Objectives We sought to determine the circadian, weekly, and seasonal variation of coronary Stent Thrombosis. Background Other adverse cardiovascular events such as acute myocardial infarction are known to have higher incidences during the early morning hours, Mondays, and winter months. Methods The Mayo Clinic Percutaneous Coronary Intervention Registry was searched for patients admitted to our center who underwent repeat percutaneous coronary intervention in a previously Stented coronary artery segment. Stent Thrombosis was confirmed by angiographic review, and date and time of symptom onset were obtained from medical records. Results We identified 124 patients with definite Stent Thrombosis and known date and time of symptom onset. In these patients, onset of Stent Thrombosis was significantly associated with time of day (p = 0.006), with a peak incidence around 7:00 am . When patients were subdivided into early Stent Thrombosis (0 to 30 days; n = 49), late Stent Thrombosis (31 to 360 days; n = 30), and very late Stent Thrombosis (>360 days; n = 45), only early Stent Thrombosis remained significantly associated with time of day (p = 0.030). No association with the day of the week was found (p = 0.509); however, onset of Stent Thrombosis did follow a significant seasonal pattern, with higher occurrences in the summer (p = 0.036). Conclusions Coronary Stent Thrombosis occurs more often in the early morning hours. Early Stent Thrombosis follows a circadian rhythm with a peak at 7:00 am . This pattern was not significant in late and very late Stent Thrombosis. Occurrences throughout the week were equally distributed, but Stent Thrombosis was more likely to occur in the summer months.

  • timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin
    American Journal of Cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary Stents treated with aspirin and coumadin, the peak incidence of Stent Thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of Stent Thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced Stent Thrombosis after successful coronary Stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from Stent implantation to Stent Thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p <0.0001). There was no significant difference between the timing of Stent Thrombosis in patients treated with abciximab in addition to ticlopidine and aspirin (median 17 hours, interquartile range 6 to 29) versus ticlopidine and aspirin patients who did not receive abciximab (median 11 hours, interquartile range 9 to 12, p = 0.57). Thus, in patients who receive coronary Stents, Stent Thrombosis occurs much earlier after the procedure in patients treated with ticlopidine and aspirin than in patients treated with anticoagulation therapy.

  • Timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin.
    The American journal of cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary Stents treated with aspirin and coumadin, the peak incidence of Stent Thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of Stent Thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced Stent Thrombosis after successful coronary Stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from Stent implantation to Stent Thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p

Stephanie H Wilson - One of the best experts on this subject based on the ideXlab platform.

  • timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin
    American Journal of Cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary Stents treated with aspirin and coumadin, the peak incidence of Stent Thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of Stent Thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced Stent Thrombosis after successful coronary Stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from Stent implantation to Stent Thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p <0.0001). There was no significant difference between the timing of Stent Thrombosis in patients treated with abciximab in addition to ticlopidine and aspirin (median 17 hours, interquartile range 6 to 29) versus ticlopidine and aspirin patients who did not receive abciximab (median 11 hours, interquartile range 9 to 12, p = 0.57). Thus, in patients who receive coronary Stents, Stent Thrombosis occurs much earlier after the procedure in patients treated with ticlopidine and aspirin than in patients treated with anticoagulation therapy.

  • Timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin.
    The American journal of cardiology, 1999
    Co-Authors: Stephanie H Wilson, Malcolm R Bell, James L Velianou, Charanjit S Rihal, David R Holmes, Peter B Berger
    Abstract:

    In patients receiving coronary Stents treated with aspirin and coumadin, the peak incidence of Stent Thrombosis occurs on the fifth and sixth days following the implantation procedure. Little is known about the timing of Stent Thrombosis in patients treated with aspirin and ticlopidine. We compared the timing of coronary Stent Thrombosis in patients treated with ticlopidine and aspirin with the timing in those receiving coumadin and aspirin. A retrospective databank analysis was performed and 39 patients were identified who experienced Stent Thrombosis after successful coronary Stent implantation. Of these, 21 had been treated with ticlopidine and aspirin and 18 with coumadin and aspirin therapy. The median time from Stent implantation to Stent Thrombosis in the ticlopidine and aspirin group was 12 hours (interquartile range 6 to 72 hours) compared with 4 days in the coumadin and aspirin group (interquartile range 21 to 68 hours) (p